Drug Trial Radar · NCT06658964
Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
48
Planned (sponsor's estimate)
Start
Nov 5, 2024
Primary completion
Dec 10, 2024
Study completion Mar 21, 2025
Sponsor
- Lead sponsor
- JemincareIndustry
- Sponsor type
- Industry
- Collaborators
- Zhejiang Hangyu Pharmaceutical Co., Ltd.
- First posted
- Oct 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of JMKX003142 in healthy subjects.
Conditions
- ADPKD (autosomal Dominant Polycystic Kidney Disease)
Interventions
Cohort 1: JMKX003142 and itraconazoleDrug
JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning. Itraconazole:Dose: 200mg once;Day5-Day7 and Day9-Day11, QD
Cohort 2: JMKX003142 and rifampicinDrug
JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning. Rifampicin:Dose: 600mg once;Day5-Day13 and Day15-Day17, QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of JMKX003142 in plasmaTime frame: approximately 5 days after JMKX003142 administered
- AUC of JMKX003142 in plasmaTime frame: approximately 5 days after JMKX003142 administered
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.